Table 1.
Summary of IC50 values measured in a SPA ligand competition assay for diverse nuclear receptors.
| AR | PPARγ | TRα | TRβ | |||
|---|---|---|---|---|---|---|
| IC50 (μM) | IC50 (μM) | IC50 (μM) | ||||
| DHT | 0.057 ± 0.006 | GW9662 | 0.23 ± 0.02 | T3* | 0.03 ± 0.02 | 0.14 ± 0.02 |
| Methyltrienolone (R1881) | 0.11 ± 0.02 | Rosiglitazone | 0.34 ± 0.08 | T4* | 1.4 ± 0.5 | 4.0 ± 2.0 |
| 17β-Estradiol | 3.2 ± 0.6 | Troglitazone | 3.70 ± 0.44 | GC1 | 1.6 ± 0.3 | 0.29 ± 0.11 |
| Cyproterone Acetate | 2.3 ± 0.4 | Lineolic Acid | 3.80 ± 0.49 | TRIAC* | 0.18 ± 0.1 | 0.07 ± 0.05 |
| Bicalutamide | 12.0 ± 2.6 | Arachidonic Acid | 4.20 ± 0.53 | T4Ac* | 10.0 ± 2.0 | 5.0 ± 2.0 |
| Progesterone | 5.0 ± 0.7 | T3Bz* | 12.0 ± 2.0 | 10.0 ± 4.0 | ||
| Hydroxyflutamide | 33.0 ± 8.0 | |||||
| Flutamide | 73.4 ± 29.3 | |||||
| Dexamethasone | 188.5 ± 100.0 | |||||
*
3,3',5-triiodo-L-thyronine sodium salt (T3); L-thyroxine (T4); 3,3’,5-triiodothyroacetic acid (TRIAC); 3,3’,5,5’-tetraiodothyroacetic acid (T4Ac); 4-(4'-Hydroxy-3'-iodophenoxy)-3,5-diiodo-benzoic acid (T3Bz).